The downside correction in NovoCure (NVCR) looks like it has run its course. NVCR is looking ready to resume its uptrend.
More from Investing
If you want to stay busy and make some money then you need to adapt to the action.
Markets appear to be pricing in a lot of bad short-term news for richly-valued companies such as Tesla, but perhaps not much risk related to potential longer-term macro headwinds.
Steady selling takes its toll on optimism and patience.